What technology area does this patent fall under?

Primary CPC classification A61K31/40. Mapped technology areas include Human Necessities.

When was this patent published?

Publication date Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Bicyclic-fused heteroaryl or aryl compounds

US10329302B2 · US · B2

Patent metadata
Field	Value
Publication number	US-10329302-B2
Application number	US-201815862691-A
Country	US
Kind code	B2
Filing date	Jan 5, 2018
Priority date	Apr 4, 2014
Publication date	Jun 25, 2019
Grant date	Jun 25, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

First claim

Opening claim text (preview).

We claim: 1. A method of treating rheumatoid arthritis in a human comprising administering to the human in need of such treatment a therapeutically effective amount of 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof. 2. A method of treating rheumatoid arthritis in a patient comprising administering to the patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient, or diluent.

Assignees

Pfizer

Classifications

A61P43/00
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
A61P37/00
Drugs for immunological or allergic disorders · CPC title
A61P9/00
Drugs for disorders of the cardiovascular system · CPC title
A61P7/00
Drugs for disorders of the blood or the extracellular fluid · CPC title
A61P35/00
Antineoplastic agents · CPC title

Patent family

Related publications grouped by family.

View patent family 52988358

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10329302B2 cover?: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Who is the assignee on this patent?: Pfizer
What technology area does this patent fall under?: Primary CPC classification A61K31/40. Mapped technology areas include Human Necessities.
When was this patent published?: Publication date Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).